Shares of BOAN BIOTECH (06955.HK) surged 11.42% in pre-market trading on Thursday, following the announcement that its drug candidate BA1302 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for two types of cancer.
According to a statement from Shandong Boan Biotechnology Co Ltd, the FDA has granted ODD to BA1302 for the treatment of Small Cell Neuroendocrine Carcinoma (SCNC) and pancreatic cancer. This significant regulatory milestone has sparked investor optimism, driving the stock's substantial pre-market rally.
The Orphan Drug Designation is a special status granted by the FDA to drugs intended to treat rare diseases or conditions. This designation provides various benefits to the developing company, including tax credits for clinical trials, exemption from user fees, and potentially seven years of market exclusivity upon approval. For BOAN BIOTECH, this development could accelerate the path to market for BA1302 and potentially boost the company's position in the competitive oncology drug market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.